CVD Risk with Long-Acting Bronchodilators Fades After One Month

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

CVD Risk with Long-Acting Bronchodilators Fades After One Month

Posted: 01/02/2018
Author:
Nicole Lou, Contributing Writer, MedPage Today, January 02, 2018
2018 News News Articles

For COPD patients, risk greatest 30 days after starting LAMAs/LABAs

Inhaled long-acting bronchodilators may carry an elevated cardiovascular risk in the first 30 days of use by patients with chronic obstructive pulmonary disease (COPD), but it tapers afterward, according to a randomized study.
1-3 of 4071 results
1 2 3 4 5 Next »

Encouraging IVL Outcomes in ISR: NCDR Analysis

Nov 25, 2024 by
Natalie Morrison, CRTonline.org

Intravascular Lithotripsy (IVL) has demonstrated “encouraging” outcomes in off-label use for the treatment of in-stent restenosis (ISR), and warrants further studies to pin-down optimal use and long-term effects, according to a new research letter analyzing NCDR data.

Study Further Clarifies Distinction Between Fibrotic and Calcific Aortic Stenosis in TAVR Patients

Nov 25, 2024 by
Will Chu, CRTonline.org

Research published in JACC: Cardiovascular Interventions identifies the significant differences between fibrotic and calcific forms of aortic stenosis (AS), as researchers reveal further insights into patient characteristics and outcomes post-transcatheter aortic valve replacement (TAVR).

Better Outcomes for Dedicated Severe Native AR TAVR Devices Vs Off-Label: Meta-Analysis

Nov 25, 2024 by
Natalie Morrison, CRTonline.org

Dedicated transcatheter aortic valve replacement (TAVR) devices led to better outcomes in high-risk severe native aortic regurgitation (AR) patients than off-label alternatives, according to a new meta-analysis in more than 2,000 patients.

1-3 of 4071 results
1 2 3 4 5 Next »

Most Viewed Pages

The Fellows Call - TCT 2024 Recap

Examining patient demographics and major adverse cardiac events following noncardiac surgery: Applying a health equity lens

Study Identifies Similar One Year Outcomes for Two Transcatheter Heart Valves

King and I | S5 E7 | Insights from the EARLY TAVRY Study

King and I | S5 E6 | Results and Implications of the ECLIPSE Study

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

CVD Risk with Long-Acting Bronchodilators Fades After One Month

For COPD patients, risk greatest 30 days after starting LAMAs/LABAs

Encouraging IVL Outcomes in ISR: NCDR Analysis

Study Further Clarifies Distinction Between Fibrotic and Calcific Aortic Stenosis in TAVR Patients

Better Outcomes for Dedicated Severe Native AR TAVR Devices Vs Off-Label: Meta-Analysis

Most Viewed Pages

Explore the Site

Stay Connected